Fulgent Genetics, Inc.
FLGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | -0.12 | -0.12 | 0.40 |
| FCF Yield | 0.73% | -6.04% | -1.76% | 3.75% |
| EV / EBITDA | -7,595.09 | -34.47 | -79.70 | -52.24 |
| Quality | ||||
| ROIC | -1.34% | -1.56% | -1.73% | -1.08% |
| Gross Margin | 42.24% | 42.10% | 38.59% | 41.79% |
| Cash Conversion Ratio | -1.63 | 1.57 | 0.37 | -4.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.28% | -0.45% | -7.11% | -22.92% |
| Free Cash Flow Growth | 113.67% | -304.38% | -143.07% | 160.61% |
| Safety | ||||
| Net Debt / EBITDA | 1,429.83 | 5.21 | 10.30 | 4.69 |
| Interest Coverage | -548.21 | -1,159.59 | -1,413.93 | -76.83 |
| Efficiency | ||||
| Inventory Turnover | 4.82 | 5.27 | 5.23 | 5.29 |
| Cash Conversion Cycle | 69.40 | 74.73 | 79.36 | 70.72 |